Drug Acetylation in Breast Cancer
Author Information
Author(s): D.J.T. Webster, D. Flook, J. Jenkins, A. Hutchings, P.A. Routledge
Primary Institution: University of Wales College of Medicine
Hypothesis
Is the acetylator phenotype an important determinant of the risk of developing breast cancer?
Conclusion
The acetylator phenotype is unlikely to be an important determinant of the risk of developing breast cancer.
Supporting Evidence
- 43% of breast cancer patients were fast acetylators, similar to the control group.
- The study involved 200 subjects, providing a larger sample size than previous studies.
- The method used for determining acetylator status was recently developed and more reliable.
Takeaway
This study looked at how a person's ability to process certain drugs might affect their risk of breast cancer, and found it doesn't seem to matter.
Methodology
The acetylator phenotype was determined using isoniazid in 100 breast cancer patients and 100 control subjects.
Potential Biases
Potential bias due to the selection of subjects and their health status.
Limitations
The study may not account for other genetic factors influencing breast cancer risk.
Participant Demographics
All participants were Caucasian females.
Statistical Information
Confidence Interval
0.76-1.45
Statistical Significance
p>0.05
Want to read the original?
Access the complete publication on the publisher's website